HopeStage
Back to all studies
CompletedNCT05531591

Depression treatment and brain markers linked to dementia risk

About this titleRead the official source — NCT05531591
Medication studyAges 60+United States + Canada
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: from 60 years. Other eligibility criteria applied.

Listed locations
Los Angeles and 3 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 1, 2019
Recruitment status
Completed
Enrollment listed in the registry
87
Sponsor
Centre for Addiction and Mental Health
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States, Canada
Age range
Over 60 Years
Official registry ID
NCT05531591
Official title
Show the full official title

RCT of Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro RCT)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Los Angeles, United States · St Louis, United States · New York, United States

1 more locations
  • Toronto, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation and Switch to nortriptyline.

Who was this study for?

This study was for people with depression. Listed age limits: from 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies